Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve

Hancock Jaffe Laboratories Inc HJLI announced two-year data post-VenoValve implantation in eight patients.
Data will be presented at the Society for Vascular Surgery (SVS) Annual Meeting.
The results showed that the reflux (the backward flow of blood) decreased from 1.95 to an average of .72 (a 63% improvement).
Disease manifestations decreased from an average of 13.38 to an average of 5.38 (a 60% improvement).
Pain decreased from an average of 7.25 to an average of .50 (an improvement of 93%).
There were no safety issues or venous ulcer recurrences.
The VenoValve is a potential treatment for chronic Venous Insufficiency (CVI), a disease when valves inside the leg's veins fail, causing blood to flow in the wrong direction and creating increased pressure inside of the veins of the leg.
Related: FDA Breakthrough Designation For Its Venous Insufficiency Device.
Price Action: HJLI shares are down 4.29% at $7.14 during the market session on the last check Thursday.